UST-CDST分類による併用免疫調節剤の使用が,ウステキヌマブで治療されたクローン病患者の臨床再発に与える影響:マルチセンター研究
Joo Hye Song1, Gyeol Seong2, Jongbeom Shin3
1Department of internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Republic of Korea.
Digestive diseases and sciences
|February 21, 2026
まとめ
ウステキヌマブ (UST) 治療に免疫調節剤を追加することで,クローン病 (CD) の再発が減少しました. USTの臨床意思決定支援ツール (UST-CDST) は,併用療法のための患者を選択するのに役立ちます.
科学分野:
- 胃腸内科 胃腸内科
- 免疫学 免疫学とは
- 薬理学 薬理学とは
背景:
- ウステキヌマブ (UST) は,アクティブなクローン病 (CD) に使用されます.
- 併用免疫調節剤とUSTの有効性,および患者の選択基準については,依然として議論されている.
- UST臨床意思決定支援ツール (UST-CDST) は,寛解を予測するために開発されました.
研究 の 目的:
- CD患者における再発に対するUSTと併用免疫調節剤の効果を評価する.
- UST-CDSTの可行性を評価し,併用免疫調節剤療法から恩恵を受ける可能性のある患者を選択する.
主な方法:
- 従来の治療法に適度から重度のCD耐性があり,USTで治療された患者も登録されました.
- 臨床再発は,特定の臨床イベントによって定義された.
- カプラン・マイヤー解析を用いて,有効性とUST-CDSTのスクリーニング能力を評価した.
主要な成果:
- 免疫調節剤の併用は,累積的な再発率 (p=0.024) が著しく低下した.
- UST-CDSTによる低〜中程度の応答者として特定された患者は,併用療法 (p=0.046) でより高い再発フリー生存期間を示しました.
- この利点は,高確率応答者 (p=0.439) で観察されなかった.
結論:
- USTと免疫調節剤の併用は,CD患者の臨床再発のリスクを軽減します.
- 組み合わせ治療の利点は,低いから中程度の確率で反応する患者で最も顕著です.
- UST-CDSTは,同時に免疫調節剤の使用に関する決定を導くためのツールとしての可能性を示しています.
関連する概念動画
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
583
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
583
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
547
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
547
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
610
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
610
Drugs for Treatment of Ulcerative Colitis in IBD
553
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
553
Inflammatory Bowel Disease IV: Pharmacological Management
832
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
832
Inflammatory Bowel Disease II: Crohn's Disease
1.3K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.3K

